Literature DB >> 24508725

Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes.

Sarah M Schumacher-Bass1, Eileen D Vesely, Lian Zhang, Katherine E Ryland, Dyke P McEwen, Priscilla J Chan, Chad R Frasier, Jeremy C McIntyre, Robin M Shaw, Jeffrey R Martens.   

Abstract

RATIONALE: Kv1.5 (KCNA5) mediates the ultra-rapid delayed rectifier current that controls atrial action potential duration. Given its atrial-specific expression and alterations in human atrial fibrillation, Kv1.5 has emerged as a promising target for the treatment of atrial fibrillation. A necessary step in the development of novel agents that selectively modulate trafficking pathways is the identification of the cellular machinery controlling Kv1.5 surface density, of which little is yet known.
OBJECTIVE: To investigate the role of the unconventional myosin-V (MYO5A and MYO5B) motors in determining the cell surface density of Kv1.5. METHODS AND
RESULTS: Western blot analysis showed MYO5A and MYO5B expression in the heart, whereas disruption of endogenous motors selectively reduced IKur current in adult rat cardiomyocytes. Dominant negative constructs and short hairpin RNA silencing demonstrated a role for MYO5A and MYO5B in the surface trafficking of Kv1.5 and connexin-43 but not potassium voltage-gated channel, subfamily H (eag-related), member 2 (KCNH2). Live-cell imaging of Kv1.5-GFP and retrospective labeling of phalloidin demonstrated motility of Kv1.5 vesicles on actin tracts. MYO5A participated in anterograde trafficking, whereas MYO5B regulated postendocytic recycling. Overexpression of mutant motors revealed a selective role for Rab11 in coupling MYO5B to Kv1.5 recycling.
CONCLUSIONS: MYO5A and MYO5B control functionally distinct steps in the surface trafficking of Kv1.5. These isoform-specific trafficking pathways determine Kv1.5-encoded IKur in myocytes to regulate repolarizing current and, consequently, cardiac excitability. Therapeutic strategies that manipulate Kv1.5 selective trafficking pathways may prove useful in the treatment of arrhythmias.

Entities:  

Keywords:  Kv1.5 potassium channel; arrhythmias, cardiac; connexin 43; heart

Mesh:

Substances:

Year:  2014        PMID: 24508725      PMCID: PMC4213814          DOI: 10.1161/CIRCRESAHA.114.302711

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  68 in total

Review 1.  Cooperation between microtubule- and actin-based motor proteins.

Authors:  S S Brown
Journal:  Annu Rev Cell Dev Biol       Date:  1999       Impact factor: 13.827

Review 2.  Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.

Authors:  Carmelo Lafuente-Lafuente; Stéphane Mouly; Miguel Angel Longás-Tejero; Isabelle Mahé; Jean-François Bergmann
Journal:  Arch Intern Med       Date:  2006-04-10

Review 3.  Functional studies of individual myosin molecules.

Authors:  Jody A Dantzig; Tim Y Liu; Yale E Goldman
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

4.  Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation.

Authors:  Timothy M Olson; Alexey E Alekseev; Xiaoke K Liu; Sungjo Park; Leonid V Zingman; Martin Bienengraeber; Srinivasan Sattiraju; Jeffrey D Ballew; Arshad Jahangir; Andre Terzic
Journal:  Hum Mol Genet       Date:  2006-06-13       Impact factor: 6.150

Review 5.  CFTR, chloride concentration and cell volume: could mammalian protein histidine phosphorylation play a latent role?

Authors:  K J Treharne; R M Crawford; A Mehta
Journal:  Exp Physiol       Date:  2005-10-11       Impact factor: 2.969

6.  Over-expression of Kv1.5 in rat cardiomyocytes extremely shortens the duration of the action potential and causes rapid excitation.

Authors:  Yasutaka Tanabe; Katsuharu Hatada; Naoki Naito; Yoshiyasu Aizawa; Masaomi Chinushi; Hiroyuki Nawa; Yoshifusa Aizawa
Journal:  Biochem Biophys Res Commun       Date:  2006-05-12       Impact factor: 3.575

Review 7.  New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.

Authors:  John W Ford; James T Milnes
Journal:  J Cardiovasc Pharmacol       Date:  2008-08       Impact factor: 3.105

8.  Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation.

Authors:  T Christ; E Wettwer; N Voigt; O Hála; S Radicke; K Matschke; A Várro; D Dobrev; U Ravens
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 9.  Safety considerations in the pharmacological management of atrial fibrillation.

Authors:  A John Camm
Journal:  Int J Cardiol       Date:  2008-01-08       Impact factor: 4.164

10.  PSD-95 and SAP97 exhibit distinct mechanisms for regulating K(+) channel surface expression and clustering.

Authors:  A M Tiffany; L N Manganas; E Kim; Y P Hsueh; M Sheng; J S Trimmer
Journal:  J Cell Biol       Date:  2000-01-10       Impact factor: 10.539

View more
  18 in total

Review 1.  Cardiomyocyte protein trafficking: Relevance to heart disease and opportunities for therapeutic intervention.

Authors:  Shaohua Xiao; Robin M Shaw
Journal:  Trends Cardiovasc Med       Date:  2014-12-29       Impact factor: 6.677

Review 2.  Na+ channel function, regulation, structure, trafficking and sequestration.

Authors:  Ye Chen-Izu; Robin M Shaw; Geoffrey S Pitt; Vladimir Yarov-Yarovoy; Jon T Sack; Hugues Abriel; Richard W Aldrich; Luiz Belardinelli; Mark B Cannell; William A Catterall; Walter J Chazin; Nipavan Chiamvimonvat; Isabelle Deschenes; Eleonora Grandi; Thomas J Hund; Leighton T Izu; Lars S Maier; Victor A Maltsev; Celine Marionneau; Peter J Mohler; Sridharan Rajamani; Randall L Rasmusson; Eric A Sobie; Colleen E Clancy; Donald M Bers
Journal:  J Physiol       Date:  2015-03-15       Impact factor: 5.182

Review 3.  Conserved roles for cytoskeletal components in determining laterality.

Authors:  Gary S McDowell; Joan M Lemire; Jean-Francois Paré; Garrett Cammarata; Laura Anne Lowery; Michael Levin
Journal:  Integr Biol (Camb)       Date:  2016-03-14       Impact factor: 2.192

4.  Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress.

Authors:  Qian Wu; Jia-Hui Tian; Yong-Xiang He; Yong-Yin Huang; Yu-Qing Huang; Gui-Ping Zhang; Jian-Dong Luo; Qin Xue; Xi-Yong Yu; Ying-Hua Liu
Journal:  Acta Pharmacol Sin       Date:  2021-01-25       Impact factor: 7.169

5.  SAP97 and cortactin remodeling in arrhythmogenic Purkinje cells.

Authors:  Wen Dun; Patrick Wright; Peter Danilo; Peter J Mohler; Penelope A Boyden
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

6.  Inhibitory effects of cholinesterase inhibitor donepezil on the Kv1.5 potassium channel.

Authors:  Kai Li; Neng Cheng; Xian-Tao Li
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

7.  Zonisamide, an antiepileptic drug, alleviates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress.

Authors:  Jia-Hui Tian; Qian Wu; Yong-Xiang He; Qi-Ying Shen; Mubarak Rekep; Gui-Ping Zhang; Jian-Dong Luo; Qin Xue; Ying-Hua Liu
Journal:  Acta Pharmacol Sin       Date:  2020-07-09       Impact factor: 6.150

8.  An N-terminal fusion allele to study melanin concentrating hormone receptor 1.

Authors:  Kalene R Jasso; Tisianna K Kamba; Arthur D Zimmerman; Ruchi Bansal; Staci E Engle; Thomas Everett; Chang-Hung Wu; Heather Kulaga; Randal R Reed; Nicolas F Berbari; Jeremy C McIntyre
Journal:  Genesis       Date:  2021-06-14       Impact factor: 2.389

9.  Identification of Region-Specific Myocardial Gene Expression Patterns in a Chronic Swine Model of Repaired Tetralogy of Fallot.

Authors:  Sabine Charron; François Roubertie; David Benoist; Virginie Dubes; Stephen H Gilbert; Marion Constantin; Delphine Vieillot; Delphine Elbes; Bruno Quesson; Pierre Bordachar; Michel Haissaguerre; Olivier Bernus; Jean-Benoit Thambo; Caroline Rooryck
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

10.  Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.

Authors:  Marguerite R Irvin; Colleen M Sitlani; James S Floyd; Bruce M Psaty; Joshua C Bis; Kerri L Wiggins; Eric A Whitsel; Til Sturmer; James Stewart; Laura Raffield; Fangui Sun; Ching-Ti Liu; Hanfei Xu; Adrienne L Cupples; Rikki M Tanner; Peter Rossing; Albert Smith; Nuno R Zilhão; Lenore J Launer; Raymond Noordam; Jerome I Rotter; Jie Yao; Xiaohui Li; Xiuqing Guo; Nita Limdi; Aishwarya Sundaresan; Leslie Lange; Adolfo Correa; David J Stott; Ian Ford; J Wouter Jukema; Vilmundur Gudnason; Dennis O Mook-Kanamori; Stella Trompet; Walter Palmas; Helen R Warren; Jacklyn N Hellwege; Ayush Giri; Christopher O'donnell; Adriana M Hung; Todd L Edwards; Tarunveer S Ahluwalia; Donna K Arnett; Christy L Avery
Journal:  Am J Hypertens       Date:  2019-11-15       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.